Quoin Pharmaceuticals price target lowered to $10 from $20 at Alliance Global

Alliance Global Partners lowered the firm’s price target on Quoin Pharmaceuticals to $10 from $20 and keeps a Buy rating on the shares. The analyst cites a slightly later anticipated launch of QRX003 for Netherton syndrome and more conservative estimates of uptake through 2030 for the target cut. The firm says interim positive data from the open-label Netherton study illustrates the initial QRX003 efficacy and safety results.